Testing lower-dose ticagrelor with aspirin after mild stroke or mini-stroke
Compares two ticagrelor and aspirin schedules in adults with mild ischemic stroke or high-risk TIA.
Plain-language title generated from the registry record
Registry title: Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Key facts
- Where
- Sari, IranSee the site
- Phase
- Phase 2/3
Where in Iran
- Mazandaran province, Sari,IranSari, IranTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mazandaran University of Medical Sciences
- Trial code
- NCT06653348
- Record updated
- 27 April 2025
- Original description
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.Read full original descriptionShow less
De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
Inclusion: signing inform consent,; recent ischemic stroke within 24 h,; diagnosed by brain CT or MRI mild stroke with NIHSS =<8 and no evidence of large infarct in brain imaging; high risk TIA with ABCD >4,; no cardioembolic source such as low E/F, MS, AF ,; no specific etiology such as dissection, vasculitis, ; no carotid stenosis > 50 % in side of involvement.
Exclusion: any indication for anticoagulant therapy; acute phase treatment with intravenous thrombolysis or thrombectomy; any contraindication for consumptive drug; history of hypersensitivity to consumptive drug; history of intracranial hemorrhage; history of GI bleeding during past 6 m; history of coagulopathy; candidate for endarterectomy; active hemorrhagic diathesis during randomization.